Jan 10, 2023

New Year’s Greetings from ProTarget

First of all, happy New Year to you all!

The year 2022 has ended and 2023 has just begun. In 2022, we achieved a number of important milestones in ProTarget. Firstly, three new sites were approved for trial initiation including site Aalborg, site Aarhus and site Herlev. ProTarget is now open in seven sites across all five regions in Denmark. Secondly, we opened two new study arms offering the drugs niraparib and pemigatinib, respectively, for patients with relevant genomic alterations. Last but not least, by the end of 2022 we reached 100 patients enrolled in treatment (figure 1). 2022 has indeed been an exciting year!

In 2023, we hope to be able to continue this successful path. We have at least one new drug in the pipeline, which we hope to make available very soon. We expect that site Goedstrup will open and are collaborating closely with the site to achieve this. Furthermore, we look forward to developing and expanding our international collaborations further through three upcoming spin-off projects supported by the EU Commission. But most of all, we look forward to continuing to provide genomic variant-matched targeted therapies for the patients in need, to provide them with new hope and time with their families.

We would like to take this opportunity to thank all our colleagues as well as collaborators for their hard work and support in ProTarget. But most importantly, we would like to thank our patients and their families for their trust in ProTarget and for participating in the trial! Based on the contributions from both patients and partners we hope to gain new knowledge in precision oncology and pave the way for personalised cancer treatment in Denmark.

Best wishes for 2023,

The ProTarget sponsor-team

Figure 1: The figure illustrates the accumulated number of patients enrolled in treatment in ProTarget.